Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed, adenocarcinoma of the prostate, clinical stage T1c-T3b, N0, M0.~2. Patient will have clinically negative nodes as established by imaging (pelvic computed tomography (CT), magnetic resonance imaging (MRI)).~3. The patient will be clinically M0.~4. Zubrod status 0-1.~5. No prior pelvic or prostate radiation or chemotherapy for prostate cancer; induction hormonal therapy beginning ≤ 120 days prior to registration is acceptable.~6. One of the following combinations of factors:~   Clinical stage T1c-T2c, Gleason score 2-6 and prostate-specific antigen (PSA) \>10 but ≤ 20 Clinical stage T3a-T3b, Gleason score 2-6 and PSA ≤ 20 Clinical stage T1c-T3b, Gleason score 7-10 and PSA ≤ 20~7. Patients must sign a study-specific consent form prior to registration.~Exclusion Criteria:~1. Stage T4 disease.~2. Lymph node involvement (N1).~3. Evidence of distant metastases (M1).~4. Radical surgery for carcinoma of the prostate.~5. Previous hormonal therapy beginning \> 120 days prior to registration.~6. Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.~7. Prior transurethral resection of the prostate (TURP).~8. Prior invasive malignancy(except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the oral cavity or bladder are permissible).~9. Hip prosthesis.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- External Beam Radiotherapy and High Dose brachytherapy boost (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).